Recombinant Human Metalloreductase STEAP1(STEAP1) CSB-CF890691HU
Specifications
| 20ug / 100ug price = 20ug |
Alternative Name(s):
Six-transmembrane epithelial antigen of prostate 1
Species: (Organism)
Homo sapiens (Human)
Gene Names:
STEAP1
Tag info:
N-terminal 10xHis-SUMO-tagged
Target Protein AA Sequence:
MESRKDITNQEELWKMKPRRNLEEDDYLHKDTGETSMLKRPVLLHLHQTAHADEFDCPSELQHTQELFPQWHLPIKIAAIIASLTFLYTLLREVIHPLATSHQQYFYKIPILVINKVLPMVSITLLALVYLPGVIAAIVQLHNGTKYKKFPHWLDKWMLTRKQFGLLSFFFAVLHAIYSLSYPMRRSYRYKLLNWAYQQVQQNKEDAWIEHDVWRMEIYVSLGIVGLAILALLAVTSIPSVSDSLTWREFHYIQSKLGIVSLLLGTIHALIFAWNKWIDIKQFVWYTPPTFMIAVFLPIVVLIFKSILFLPCLRKKILKIRHGWEDVTKINKTEICSQL
Expression Region:
1-339aa
Subcellular Location:
Endosome membrane, Multi-pass membrane protein
Tissue Specificity:
Ubiquitously expressed. Highly expressed in prostate tumors.
Protein Length:
Full Length
Pathway:
Mol. Weight:
58.4 kDa
Purity:
Greater than 90% as determined by SDS-PAGE.
Form:
Liquid or Lyophilized powder
Buffer:
If the delivery form is liquid, the default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol. If the delivery form is lyophilized powder, the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.
Research Areas:
Tags & Cell Markers
Function:
Metalloreductase that has the ability to reduce both Fe(3+) to Fe(2+) and Cu(2+) to Cu(1+). Uses NAD(+) as acceptor (By similarity).
Involvement in disease:
Relevance:
Metalloreductase that has the ability to reduce both Fe3+ to Fe2+ and Cu2+ to Cu1+. Uses NAD+ as acceptor
Reconstitution:
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20℃/-80℃. Our default final concentration of glycerol is 50%. Customers could use it as reference.
Protein Families:
STEAP family
Reference:
"STEAP: a prostate-specific cell-surface antigen highly expressed in human prostate tumors." Hubert R.S., Vivanco I., Chen E., Rastegar S., Leong K., Mitchell S.C., Madraswala R., Zhou Y., Kuo J., Raitano A.B., Jakobovits A., Saffran D.C., Afar D.E.H. Proc. Natl. Acad. Sci. U.S.A. 96:14523-14528(1999)
